What question did this study set out to answer?

This research investigates the prevalence and impact of frailty, multimorbidity, and polypharmacy on health outcomes in hospitalized older adults.

June 29, 2026Open Access

Prevalence of frailty, multimorbidity, and polypharmacy and their association with health outcomes in hospitalized older adults: a prospective multicenter cohort study

AAAnan Al-JabriOman Medical College ZAZubaida Al-FalahiSultan Qaboos University Hospital JAJuhaina Salim Al-MaqbaliSultan Qaboos University Hospital

Key Points

This research investigates the prevalence and impact of frailty, multimorbidity, and polypharmacy on health outcomes in hospitalized older adults.
Prospective multicenter cohort study conducted in two tertiary hospitals in Oman
Patients aged ≥ 65 years assessed for frailty, multimorbidity, and polypharmacy
Clinical outcomes evaluated included length of stay, in-hospital mortality, and readmissions
37.67% of patients had high frailty, 34.15% had complex multimorbidity, and 65.85% had polypharmacy.
Higher frailty was linked to longer hospital stays (6.49 vs. 4.88 days, p < 0.01) and increased in-hospital mortality (15.11% vs. 3.54%, p < 0.01).
High frailty independently predicted 30-day mortality (aOR 5.68, p < 0.01) and 90-day mortality (aOR 3.53, p < 0.01).

Abstract

The growing burden of frailty, multimorbidity, and polypharmacy among older adults presents major challenges to healthcare systems worldwide. These interrelated conditions are known to worsen clinical outcomes, yet data from the region are limited. This study aimed to examine the prevalence and clinical impact of frailty, complex multimorbidity, and polypharmacy among hospitalized older adults in Oman. A prospective, multicenter cohort study was conducted in general internal medicine wards of two tertiary hospitals in Oman. Patients aged ≥ 65 years were consecutively enrolled and assessed for frailty using Clinical Frailty Scale (CFS), multimorbidity using the Charlson Comorbidity Index (CCI) and a definition of complex multimorbidity (≥ 3 chronic conditions), and polypharmacy (≥ 5 medications). Clinical outcomes included hospital length of stay (LOS), in-hospital mortality, HD/ICU admission, 30- and 90-day mortality, and 30- and 90-day readmission. Multivariable regression and Kaplan-Meier survival analyses were used. Among 369 patients, high frailty, complex multimorbidity, and polypharmacy were present in 139 (37.67%), 126 (34.15%), and 243 (65.85%) patients, respectively. Higher frailty was associated with longer LOS (6.49 vs. 4.88 days, p < 0.01) and increased in-hospital mortality (15.11% vs. 3.54%, p < 0.01). High frailty independently predicted 30-day mortality (adjusted odds ratio aOR 5.68, p < 0.01) and 90-day mortality (aOR 3.53, p < 0.01). Complex multimorbidity independently predicted 30-day readmission (aOR 1.92, p = 0.015), 30-day mortality (aOR 2.12, p = 0.026), and 90-day mortality (aOR 2.42, p < 0.01). Kaplan–Meier and adjusted Cox regression analyses showed lower 90-day survival and higher mortality risk among patients with high frailty (adjusted hazard ratio aHR 3.16, 95% CI 1.69–5.89, p < 0.001) and complex multimorbidity (aHR 1.85, 95% CI 1.15–2.98, p = 0.011). Frailty, complex multimorbidity, and polypharmacy were common among hospitalized older adults in Oman. High frailty and complex multimorbidity were the most consistent predictors of adverse outcomes, supporting early recognition, structured geriatric assessment pathways, and future targeted patient-centered interventions.

KI fragen

Bookmark

View Full Paper